Subcutaneous Administration of Behaviorally Effective Doses of Arginine Vasopressin Change Brain AVP Content Only in Median Eminence
- 1 January 1986
- journal article
- research article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 42 (3) , 260-266
- https://doi.org/10.1159/000124449
Abstract
The accumulation of [8-arginine]vasopressin (AVP) in brain areas inside the blood-brain barrier (thalamus-hypothalamus, amygdala with overlying temporal cortex, hippocampus and cerebral cortex) and outside the blood-brain barrier (median eminence of the hypothalamus and area postrema) was measured after subcutaneous injection of the hormone. The plasma concentrations of AVP peaked at 5 min after subcutaneous injection and declined in a biphasic manner over the next 115 min. The concentration of AVP in brain tissue samples peaked at 20 min after the subcutaneous injection of AVP; the decline of AVP in the areas protected by the blood-brain barrier followed the time course seen for plasma. The concentration of AVP in the brain areas not so protected also peaked at 20 min but these declined at rates that differed from other brain areas and plasma. The concentration of AVP in the plasma and in most brain areas depended on the dose administered, while those in the median eminence and in the area postrema did not. Water deprivation for 24 and 48 h significantly elevated both the plasma AVP concentration and the concentration of AVP in the hypothalamus and in the amygdala-temporal cortex samples. The increases in AVP after water deprivation are limited to these two regions and are quantitatively much lower than after peripheral administration. Furthermore, when the brains of anesthetized rats were perfused free of blood, there were no changes in regional brain AVP content after subcutaneous treatment with 5,000 ng/kg of AVP, except for the median eminence. These data suggest that circulating AVP does not enter the parenchyma of brain areas protected by the blood-brain barrier in sufficient quantities to be detected by our assay. The penetration of AVP into areas not protected by the blood-brain barrier may be due to differences in the specialized cellular components located there. These results support the hypothesis that centrally and peripherally derived AVP may each act on different substrates to effect body function.Keywords
This publication has 11 references indexed in Scilit:
- Can aversive properties of (peripherally-injected) vasopressin account for its putative role in memory?Behavioural Brain Research, 1983
- Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): Half-times of disappearance of these neuropeptides from CSFBrain Research, 1983
- Localization of immunoreactive prolactin in ependyma and circumventricular organs of rat brainCell and tissue research, 1982
- Vasopressin Exhibits a Rhythmic Daily Pattern in Cerebrospinal Fluid But Not in BloodScience, 1981
- Arginine vasopressin and a vasopressin antagonist peptide: Opposite effects on extinction of active avoidance in ratsRegulatory Peptides, 1981
- INDICATIONS FOR A BRAIN UPTAKE OF LABELED VASOPRESSIN AND OXYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER1979
- Design of potent antagonists of the vasopressor response to arginine-vasopressinJournal of Medicinal Chemistry, 1978
- Transport function of hypothalamic tanycyte ependyma: How good is the evidence?Neuroscience, 1978
- Effect of desglycinamide-lysine vasopressin (DG-LVP) on sexually motivated T-maze behavior of the male ratHormones and Behavior, 1977
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951